AI-BASED PRECISION DIAGNOSTICS TO IMPROVE CANCER TREATMENT DECISIONS AND PATIENT OUTCOMES
A CE-IVD solution for risk profiling of breast cancer,
the first-of-its-kind
From research to clinical use
Stratipath is leveraging state-of-the-art deep learning technologies (AI) to provide risk profiling of cancer tumours.
Follow the news about Stratipath.
Join our mission to improve patient outcomes.
Co-founder and professor of pathology, Johan Hartman, explains Stratipath in this 3 min video.
Stratipath is a spin-out of Karolinska Institutet in Stockholm, Sweden, leveraging state-of-the-art deep learning technologies (AI) to provide risk profiling of cancer tumours to healthcare and life science companies. Our cloud-based SaaS solutions are being used in clinical settings, having been developed based on years of ground-breaking research. We make precision diagnostics available to more patients at an affordable cost and in a fraction of the time compared to traditional methods.
Stratipath breast
Addresses the over 50% of breast cancers that are diagnosed as intermediate risk
Deep learning analysis of routine HE-stained histopathology images from resected breast tumours
Rapid analysis can shorten time to treatment
Contributes to reduced costs, time and workload
“Stratipath Breast offers a faster and cheaper alternative to molecular assays, allowing more patients to have access to precision diagnostics. By using Stratipath Breast, clinicians can diagnose with support from prognostic information, while reducing laboratory time and costs.”
Johan Hartman
Professor of pathology at Karolinska Institutet, Stockholm and co-founder of Stratipath.
Stratipath breast
Addresses the over 50% of breast cancers that are diagnosed as intermediate risk
Deep learning analysis of routine HE-stained histopathology images from resected breast tumours
Rapid analysis can shorten time to treatment
Contributes to reduced costs, time and workload
“Stratipath Breast offers a faster and cheaper alternative to molecular assays, allowing more patients to have access to precision diagnostics. By using Stratipath Breast, clinicians can diagnose with support from prognostic information, while reducing laboratory time and costs.”
Johan Hartman
Professor in pathology at Karolinska Institutet, Stockholm and co-founder of Stratipath.
A paradigm shift in prognostic risk stratification of breast cancer, providing an alternative to expensive and time-consuming molecular assays.
For commercial rollout, distribution and optimal clinical workflow. SaaS solution integrated with leading digital pathology solutions.
In healthcare – oncology clinics and pathology labs.
AI platform enabling rapid development, validation and deployment of AI-based precision diagnostics.
Published in high-impact journals and ongoing studies to support current and future solutions.
A paradigm shift in prognostic risk stratification of breast cancer, providing an alternative to expensive and time-consuming molecular assays.
For commercial rollout, distribution and optimal clinical workflow. SaaS solution integrated with leading digital pathology solutions.
In healthcare – oncology clinics and pathology labs.
AI platform enabling rapid development, validation and deployment of AI-based precision diagnostics.
Published in high-impact journals and ongoing studies to support current and future solutions.
